| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |